Results 271 to 280 of about 12,002 (336)

Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications

Advanced Drug Delivery Reviews, 2023
RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable diseases and genetic disorders by regulating disease-related gene expression. The successful development of COVID-19 mRNA vaccines further emphasizes the potential of RNA therapeutics in the prevention of infectious diseases as well as in the treatment of chronic ...
Michaela Jeong, Yeji Lee, Jeongeun Park, Hyein Jung, Hyukjin Lee   +4 more
openaire   +3 more sources

P23-01: Occupational Exposure Limit (OEL) for Lipid Nanoparticles (LNPs)

Toxicology Letters, 2023
L. Wiesner, M. Cerne, M. Schmitz, T. Bell, E. Lovsin Barle   +4 more
openaire   +2 more sources

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Advanced Materials, 2023
Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins ...
Yan Zong, Yi Lin, Tuo Wei, Qiang Cheng
openaire   +2 more sources

Elucidating the Immunogenic Mechanisms of Merck’s Lipid Nanoparticle (LNP) Adjuvants

The Journal of Immunology, 2023
Abstract Lipid nanoparticles (LNPs) have been shown to be a safe and potent platform for vaccine delivery. When added to subunit proteins, they have the potential to induce strong immune responses capable of generating long-lasting immunity. Merck has developed a variety of LNPs utilizing different cationic lipid components including LNP
Nicole L Sullivan, Susan Secore, Antonia Bass, Mary Wolf, Andrew Dangizer, Nithya Thambi, Shashwati Bhattacharya, Silveria Rodriguez, Gregory L O’Donnell, Andrew L Bett   +9 more
openaire   +1 more source

Elucidating the Immunogenic Mechanisms of Merck’s Lipid Nanoparticle (LNP) Adjuvants

The Journal of Immunology, 2022
Abstract Adjuvants are crucial components of subunit vaccines, as they help induce immune responses to poorly immunogenic antigens. Merck has developed a variety of lipid nanoparticles (LNPs) that contain different cationic lipids, a critical component that is mainly responsible for the reactogenicity induced by the LNP.
Antonia R Bass, Sonya Kimball, Anjelica Jenkins, Aimee Burton, Katherine Trostle, Halea Corcoran, Meredith Allen, Catherine Gallagher, Jacque Harms, Andrew Bett, Nicole Sullivan   +10 more
openaire   +1 more source

Chitosan-lipid nanoparticles (CS-LNPs): Application to siRNA delivery

Journal of Colloid and Interface Science, 2018
To benefit from the biocompatibility of lipid nanoparticles associated with the transfection ability of chitosan, small chitosan lipid nanoparticles (CS-LNPs) dedicated to SiRNA delivery were formulated by an easy-to-implement one-step process. Formulations of CS-LNPs (lipid core stabilized by a shell comprising phospholipids/cationic lipids and ...
Tezgel, Ozgul, Szarpak-Jankowska, Anna, Arnould, Amandine, Auzély-Velty, Rachel, Texier, Isabelle   +4 more
openaire   +4 more sources

Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)

Biomaterials Science, 2022
Alteration of phospholipid chemistry in lipid nanoparticles (LNPs) can increase endosomal escape and control organ targeting.
Ester Álvarez-Benedicto, Lukas Farbiak, Martha Márquez Ramírez, Xu Wang, Lindsay T. Johnson, Osamah Mian, Erick D. Guerrero, Daniel J. Siegwart   +7 more
openaire   +2 more sources

Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases

Journal of Controlled Release
Neurodegenerative diseases (NDD) are characterized by the progressive loss of neurons and the impairment of cellular functions. Messenger RNA (mRNA) has emerged as a promising therapy for treating NDD, as it can encode missing or dysfunctional proteins and anti-inflammatory cytokines or neuroprotective proteins to halt the progression of these diseases.
Seyedeh Ghazal, Moosavi, Niloufar, Rahiman, Mahmoud Reza, Jaafari, Leila, Arabi   +3 more
openaire   +2 more sources

The Delivery of ABE mRNA to the Adult Murine Liver by Lipid Nanoparticles (LNPs)

2023
A genetic disorder is a disease caused by an abnormal DNA sequence, and almost half of the known pathogenic monogenetic mutations are caused by G-to-A mutation (Landrum et al., Nucleic Acids Res 44:D862-868, 2016). Adenine base editors (ABE), developed from the CRISPR, hold the great promise to mediate the A-to-G transition in genomic DNA while not ...
Dong, Yang, Chun-Qing, Song
openaire   +2 more sources

Advances in Nebulized Lipid Nanoparticles (LNPs) for Nucleic Acid Delivery

Theoretical and Natural Science
Lipid nanoparticles (LNPs) exhibit significant potential as highly efficient carriers for nucleic acid therapeutics in the treatment of pulmonary diseases.
Wenyu Zhao
semanticscholar   +1 more source